Stock Price Movement and Market Context
On 20 Jan 2026, Brooks Laboratories Ltd’s share price declined by 2.02%, closing at Rs.66, the lowest level recorded in the past year. Despite this drop, the stock marginally outperformed its Pharmaceuticals & Biotechnology sector by 0.75% on the day. However, it remains substantially below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.
The broader market context shows the Sensex index also experienced a decline, falling by 256.49 points (-0.35%) to 82,950.89 after a flat opening. The Sensex is currently trading 3.87% below its 52-week high of 86,159.02 and has recorded a three-week consecutive fall, losing 3.28% over this period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating some underlying market resilience despite recent weakness.
Long-Term Performance and Relative Comparison
Brooks Laboratories Ltd’s one-year performance starkly contrasts with the broader market. The stock has depreciated by 59.07% over the last 12 months, whereas the Sensex has appreciated by 7.60% during the same period. The stock’s 52-week high was Rs.173.65, underscoring the extent of the decline from its peak.
Over the last three years, one year, and three months, Brooks Laboratories has underperformed the BSE500 index, reflecting challenges in maintaining competitive growth and profitability relative to its peers.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Fundamental Metrics and Financial Health
Brooks Laboratories Ltd’s fundamental indicators reveal areas of concern that have contributed to its subdued market performance. The company’s long-term Return on Equity (ROE) averages a modest 2.42%, indicating limited profitability relative to shareholder equity. Net sales have grown at an annualised rate of 4.36% over the past five years, reflecting slow expansion in revenue generation.
Debt servicing capacity is notably weak, with an average EBIT to interest ratio of -3.69, suggesting difficulties in covering interest expenses from operating earnings. This metric highlights financial strain that may affect the company’s ability to manage its liabilities effectively.
Despite these challenges, the company has reported positive results for four consecutive quarters, with net sales in the latest six months reaching Rs.48.96 crores, representing a growth rate of 26.45%. Profit before tax excluding other income (PBT less OI) for the most recent quarter stood at Rs.7.59 crores, an increase of 2563.2% compared to the previous four-quarter average. Operating cash flow for the year reached Rs.2.63 crores, the highest recorded in recent periods.
Valuation and Market Perception
Brooks Laboratories currently holds a Mojo Score of 37.0 and a Mojo Grade of Sell, an improvement from its previous Strong Sell rating as of 22 Dec 2025. The company’s market capitalisation grade is rated 4, reflecting its relative size and market standing.
The stock trades at a Price to Book Value of 1.7, which is considered very attractive relative to its peers’ historical valuations. The company’s ROE for the latest period has improved to 12.1, indicating some enhancement in profitability metrics. Additionally, the price-to-earnings-to-growth (PEG) ratio stands at 0.1, suggesting the stock is valued at a discount when considering its profit growth of 170.3% over the past year.
Shareholding and Sector Positioning
The majority shareholding remains with promoters, maintaining a stable ownership structure. Brooks Laboratories operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance amid broader market fluctuations. The stock’s recent price action and fundamental data indicate ongoing challenges in regaining momentum within this competitive industry.
Holding Brooks Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Recent Trends
Brooks Laboratories Ltd’s stock has experienced a significant decline over the past year, culminating in the recent 52-week low of Rs.66. While the company has demonstrated some positive quarterly results and improved profitability metrics, these have not yet translated into sustained upward price momentum. The stock remains below all major moving averages, reflecting continued investor caution.
The company’s long-term growth rates and financial ratios suggest a cautious outlook, with slow revenue expansion and limited capacity to service debt. Despite a more favourable valuation compared to peers, the stock’s performance relative to the broader market and sector remains subdued.
Market conditions, including a weakening Sensex and sector pressures, have compounded the stock’s challenges. The recent downgrade from Strong Sell to Sell indicates a slight improvement in sentiment but underscores ongoing concerns about the company’s fundamentals and market position.
Unlock special upgrade rates for a limited period. Start Saving Now →
